Gateway Investment Advisers LLC increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 517,420 shares of the medical equipment provider’s stock after acquiring an additional 21,719 shares during the quarter. Gateway Investment Advisers LLC owned approximately 0.19% of Hologic worth $22,120,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently made changes to their positions in HOLX. Grove Bank & Trust boosted its position in shares of Hologic by 115.8% during the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after acquiring an additional 1,535 shares during the last quarter. Hall Laurie J Trustee boosted its position in shares of Hologic by 10.2% during the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after acquiring an additional 225 shares during the last quarter. Commonwealth Bank of Australia boosted its position in shares of Hologic by 31.0% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after acquiring an additional 600 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new position in shares of Hologic during the 2nd quarter valued at about $191,000. Finally, National Asset Management Inc. acquired a new position in shares of Hologic during the 2nd quarter valued at about $203,000. 97.58% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $50.00 price target (up previously from $48.00) on shares of Hologic in a research report on Tuesday, January 9th. BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. Cowen raised shares of Hologic to a “buy” rating and set a $52.00 target price on the stock in a research report on Wednesday, December 20th. Bank of America raised shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 target price on the stock in a research report on Thursday, January 4th. Finally, Evercore ISI initiated coverage on shares of Hologic in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $50.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $48.79.
In other news, VP Karleen Marie Oberton sold 1,023 shares of the stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $39.84, for a total transaction of $40,756.32. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Elaine Ullian sold 9,282 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The disclosure for this sale can be found here. Insiders have sold 12,099 shares of company stock worth $487,223 in the last three months. Corporate insiders own 0.79% of the company’s stock.
Hologic, Inc. (NASDAQ:HOLX) opened at $44.00 on Thursday. The company has a market cap of $12,061.16, a PE ratio of 16.67, a price-to-earnings-growth ratio of 2.09 and a beta of 0.95. Hologic, Inc. has a 1 year low of $35.76 and a 1 year high of $46.80. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The business had revenue of $802.90 million for the quarter, compared to analysts’ expectations of $792.54 million. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The business’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.52 earnings per share. equities research analysts forecast that Hologic, Inc. will post 2.15 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/18/gateway-investment-advisers-llc-purchases-21719-shares-of-hologic-inc-holx.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.